|
|
| Industrie Pharmaceutique > Etude de marché sectorielle |
| Pfizer Inc - Company Profile, Financials and Snapshot Data |
|
|
|
|
€ 15,00 |
Editeur
: |
Research bank |
Langue
: |
Anglais |
Date de publication : |
Avril 2007 |
Taille du document : |
4 |
Autres informations : |
Description , Table des matières |
| |
|
|
|
|
| |
Documents Publics |
1,200,000
documents |
Téléchargement illimités |
|
|
|
Etudes Privées |
50,000 rapports et études |
Paiement à la piéce |
|
|
|
|
| |
|
1.Télécharger nos rapports publics
Accés complet à plus de 1,2 Million de documents publics : études de marché, statistiques sectorielles, fiches pays, monographie d'entreprises, veille concurentielle, rapports annuels...
|
| Nos documents publics sur le même théme (2) |
|
|
|
| 67 pages | Janvier 2005 | Anglais
|
|
|
| Main
focus: |
financials
|
| Research
focus: |
market definition,competition analysis |
| Geographic
focus: |
usa |
| |
|
|
|
|
| 45 pages | Avril 2004 | Anglais
|
|
|
| Main
focus: |
financials,financial analytics,wifi
|
| Research
focus: |
competition analysis,industry structure, |
| Geographic
focus: |
usa,france,united kingdom,germany |
| |
|
|
|
|
| Autres recherches sur le même thème |
|
|
|
| |
| |
|
| |
|
2.
Rechercher d'autres rapports et études à commander
Rechercher et commander ici parmi 50.000 études de marché publiées par les principaux instituts d'études internationaux
|
| Rapports privés en relation |
|
Pain Therapeutics: A Strategic Re-evaluation.
198 pages | Août 2000 |
Pain management, though not a life-threatening disease, will have its proper place in the future healthcare system because the disability and economic loss in addition to personal suffering caused |
955,00 €
|
| |
| |
Obesity Drug Markets in the US and EU: Analysis of product pipelines and the competitive environment
148 pages | |
Obesity Drug Markets in the US and EUAnalysis of product pipelines and competitive environmentBusiness Intelligence for the Pharmaceutical IndustryBusiness Insights' portfolio of healthcare management |
3 068,00 €
|
| |
| |
Regulatory Affairs: Paths to Approval
113 pages | Février 1999 |
Area Specific Chapters : The regulatory systems governing clinical trials and drug approvals are examined for the US, Europe, and Australia, Canada and Japan, including analysis of the implicatio |
795,00 €
|
| |
| |
MarketWatch: Biotechnology
32 pages | |
Datamonitor's Biotechnology MarketWatch is a one-stop news shop for time-pressed executives.
It provides monthly insight into the key events in the Biotechnology industry.
The report contains th |
160,00 €
|
| |
| |
Commercial and Pipeline Insight: Fibromyalgia - Approvals legitimize condition and expose underserved patient population
193 pages | |
IntroductionWith a considerable patient potential and large medical unmet need, the untapped fibromyalgia market represents a lucrative opportunity for pharmaceutical companies.
Estimated to total |
12 160,00 €
|
| |
| |
Commercial and Pipeline Insight: Vaccines for Adults and the Elderly - New blockbuster opportunities ahead
161 pages | |
IntroductionVaccines have re-emerged as successful revenue generators for Big Pharma, with adults and the elderly now increasingly coming into focus as the next big opportunity in this sector.
An a |
12 320,00 €
|
| |
| |
Top Ten and Emerging Pharmaceutical markets
214 pages | Juillet 1999 |
Introduction : Provides the background to the report by identifying the major trends within global healthcare markets and how these interact and influence the markets for pharmaceuticals.
Mar |
795,00 €
|
| |
| |
The Pharmaceutical Outsourcing Outlook 1998-2003
199 pages | Juin 1999 |
The streamlining of pharmaceutical companies that has taken place in recent years has allowed them to focus resources and investment on core specialities.
This, in turn, has led to a greater re |
795,00 €
|
| |
| |
Healthcare In Scotland
52 pages | Mai 2000 |
The Scottish Presentation Includes:- The Structure Of The NHS In Scotland- The Funding Of The NHS In Scotland- Distribution Of The NHS Budget In Scotland- Segmentation Of Expenditure - Total Capital E |
327,00 €
|
| |
| |
Global Pharmaceutical: a market, company and disease analysis
150 pages | Octobre 1998 |
What will drive pharmaceutical market growth into the 21st Century? What are the key challenges facing pharmaceutical manufacturers? Who are the market leaders in each sector? What strategies ar |
795,00 €
|
| |
| |
|
| |
| Autres secteurs en relation |
|
|
|
| |
|
| |
| |
| Présentation de l'étude de marché - Description & Table des matières |
|
| Pfizer Inc - Company Profile, Financials and Snapshot Data |
|
|
This report provides an in-depth company profile for Pfizer Inc ranked 101st in the 2006 Fortune Global 500. All data is gathered from primary source. Reports are available in easily accessible PDF format and data is consistently presented. Data is regularly tracked and enhanced to ensure data on this high profile company is accurate and current. This report is an indispensable tool for individuals wanting to gather the relevant facts on Pfizer Incand the industry it operates in. Research Bank concentrates on a small number of high profile companies using tested and trusted research and editorial methodologies.
|
|
This report provides the following corporate data where available:- • Company Name • Company Variant Name • Address • Primary Telephone Number • Primary Fax Number • Email • Website • SIC Codes • Date of Establishment • Stock Exchange and Ticker • Competitors • Activities Description • Fast Facts (with quick and relevant information such as segment information, R&D Expenditure, Geographic Information etc) • Board of Directors • Senior Management and Key Decision Makers • Executive Biographies • Selected Financial Data covering 4 Years (Sales, PBT, PAT, Shareholders' Equity, Total Assets, EPS and Dividends) • Analyst Coverage • Trade Names • Locations
|
|
|
PPLSEN
|
|
|
|
|
